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Herpes simplex virus-1 (HSV-1) infection of the cornea leads to a potentially blinding condition termed herpetic stromal keratitis
(HSK). Clinical studies have indicated that disease is primarily associated with recurrent HSK following reactivation of a latent
viral infection of the trigeminal ganglia. One of the key factors that limit inflammation of the cornea is the expression of Fas ligand
(FasL). We demonstrate that infection of the cornea with HSV-1 results in increased functional expression of FasL and that mice
expressing mutations in Fas (lpr) and FasL (gld) display increased recurrent HSK following reactivation compared to wild-type
mice. Furthermore, both gld and lpr mice took longer to clear their corneas of infectious virus and the reactivation rate for these
strains was significantly greater than that seen with wild-type mice. Collectively, these findings indicate that the interaction of Fas
with FasL in the cornea restricts the development of recurrent HSK.

1. Introduction
Herpetic stromal keratitis (HSK) is a potentially blinding
corneal inflammation that accompanies herpes simplex virus
(HSV) infection of the eye. The disease course in HSK begins
with a primary infection by HSV followed by a period during
which the virus enters latency in sensory and autonomic
ganglia. Many studies have shown that clinical disease is the
result of a cocktail of inflammatory cells, consisting of PMNs,
macrophages, and T cells (both CD4+ and CD8+ ) that are
recruited to the corneas of patients with HSK [1–4].
In the face of this potentially blinding inflammatory
attack, the cornea has the ability to reduce inflammation. This
includes the presence of immunosuppressive factors such as
TGF-𝛽 [5], lack of vascularization [6, 7], and the presence of
Fas ligand (FasL) [8–14].
Studies from our laboratory as well as the laboratories
of others have demonstrated that the presence of FasL in
the eye is an important barrier to both inflammatory cells
[8, 9, 12] and new blood vessels [10, 11, 13, 14]. In fact, we know
that control of inflammation is required for the immune

privilege of the eye [8, 9]. FasL expressed on ocular tissues
induces apoptosis in Fas+ lymphoid cells that invade the eye
in response to viral infection [8] or corneal grafting [11, 12, 14].
FasL expressed in the retina and the cornea also controls
new vessel growth beneath the retina and in the cornea
by inducing apoptosis of Fas-expressing vascular endothelial
cells [15–17]. These studies clearly indicate that the presence
of FasL in ocular tissues restricts inflammatory responses.
Recently we published that the interaction of Fas with
FasL is an important factor in controlling HSK during acute
infection of the cornea [18]. We demonstrated that mice
expressing mutations in Fas (lpr) or FasL (gld) experience
significantly worse ocular disease than do wild-type mice
regardless of mouse or viral strain [18]. However, since acute
infection rarely leads to clinical disease in humans and factors
important in acute infection do not display an analogous
role during recurrent infection [19], we thought it is very
important to address the role that Fas and FasL play during
recurrent disease when the virus is reactivated from latency.
In order to address the role of Fas-FasL interactions during
recurrent HSK, we have evaluated this interaction in a mouse
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model of induced recurrent HSK. We report here that mice
that are defective in either Fas or FasL experience increased
recurrent HSK disease following infection with HSV-1.

2. Materials and Methods
2.1. Virus and Cells. The virus used in these studies was the
McKrae strain of HSV-1. A plaque-purified stock was grown
and assayed on Vero cells in minimum essential medium with
Earle’s balanced salts (MEM-EBS) containing 5% fetal bovine
serum, 100 U/mL penicillin, and 100 𝜇g/mL streptomycin
[20]. Virus titers in eye swabs were determined by standard
plaque assay [20].
2.2. Mice. Investigations with mice conformed to the Association for Research in Vision and Ophthalmology (ARVO)
Statement for the Use of Animals in Ophthalmic and Vision
Research. C57BL/6 (B6) and BALB/c mice were purchased
from NCI. The B6Smn.C3-Tnfsf6gld /J and B6.MRL-Tnfsf6lpr /J
mice were purchased from Jackson Labs and maintained in
our colony. For the purposes of this paper we will refer to
these mice as B6-gld and B6-lpr, respectively. We also bred the
B6-gld and B6-lpr mice to BALB/c mice for a minimum of 12
generations. The resultant strains designation will be C.B6Tnfsf6gld and C.B6-Tnfsf6lpr [21, 22]. However, we will refer
to them as BALB-gld and BALB-lpr, respectively. In order
to assure that these mice retain their mutations, tail DNA is
isolated from individual mice and PCR tested for either the
gld or the lpr mutation.
2.3. Infection of Mice. 6–12-week-old mice were infected on
the scarified cornea with 106 PFU HSV-1 McKrae strain as
previously described [23]. Each mouse received an intraperitoneal (IP) injection of 0.5 mL pooled human serum (Sigma
Chemicals, St. Louis MO; ED50 for virus neutralization =
1 : 1600) concurrent with infection. Administration of pooled
human serum which is the source of anti-HSV antibodies
at the time of ocular infection has been shown to protect
mice from death and corneal disease during primary infection, while allowing for the establishment of latency and
subsequent reactivation of virus after corneal UV-B exposure.
These human antibodies are undetectable at the time of UV-B
irradiation 5 weeks after primary infection. HSV positive eye
swabs obtained three days after application of virus confirm
primary infection.
2.4. UV-B Irradiation and Virus Reactivation. Mice were
reactivated from latency as previously described [24]. Briefly,
the eyes of all latently infected mice were examined for
corneal opacity before irradiation, and only animals with
clear corneas were used. At least 5 weeks after primary infection, at which time human antibodies cannot be detected,
the eyes of latently infected and control mock-infected mice
were exposed to 250 mJ/cm2 of UV-B light using a TM20
Chromato-Vue transilluminator (UVP, Inc., San Gabriel,
CA), which emits UV-B at a peak wavelength of 302 nm.
Irradiated mice were swabbed with sterile cotton applicators
from day 0 to day 7, unless otherwise indicated. The swab
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material was cultured on Vero cells, as described above, in
order to detect recurrent virus shedding from the cornea.
Reactivation was defined as the finding of any HSV positive
eye swab on any days after UV-B exposure, with day 0 swabs
serving as a control.
2.5. Clinical Evaluation. On the designated days after viral
infection or UV-B reactivation, a masked observer examined
mouse eyes through a binocular-dissecting microscope in
order to score clinical disease. Stromal opacification was rated
on a scale of 0 to 4, where 0 indicates clear stroma, 1 indicates
mild stromal opacification, 2 indicates moderate opacity with
discernible iris features, 3 indicates dense opacity with loss of
defined iris detail except pupil margins, and 4 indicates total
opacity with no posterior view. Corneal neovascularization
was evaluated as described [20, 21] using a scale of 0–8, where
each of four quadrants of the eye is evaluated for the amount
of vessels that have grown into them. Periocular disease was
measured in a masked fashion on a semiquantitative scale as
previously described [25].
2.6. Viral Tittering from Tissues. Eye swab material was
collected and assayed for virus by standard plaque assay
as previously described [20]. Trigeminal ganglia and 6 mm
biopsy punches of periocular skin were removed and placed
in preweighed tubes containing 1 mm glass beads and
1 mL of medium. Trigeminal ganglia and periocular skin
homogenates were prepared by freezing and thawing the
samples, mechanically disrupting in a Mini-Beadbeater-8
(Biospec Products, Bartlesville, Oklahoma), and sonicating.
Homogenates were assayed for virus by standard plaque assay,
and the amount of virus was expressed as PFU per milliliter
of tissue homogenate.
2.7. Assays of Antibody Titers. Serum was collected from mice
at weekly intervals following infection and examined for
HSV-specific antibody content as previously described [26].
Briefly, for enzyme linked immunosorbent assays (ELISA),
serial fourfold dilutions of mouse serum were incubated
for 2 hours in duplicate wells of a 96-well plate coated
with purified HSV-1 glycoprotein. Biotinylated goat antimouse IgG was subsequently used in a colorimetric assay to
determine specific IgG amounts based on comparison to a
standard curve generated as previously described [26].
2.8. Real-Time PCR Analysis for Herpes Genome. DNA was
isolated using a DNeasy tissue preparation kit (Qiagen,
Valencia, CA). The number of latent genomes per trigeminal
ganglion was determine by real-time PCR essentially as
described [27]. Briefly, a 70 bp fragment of the thymidine
kinase (tk) gene was amplified from trigeminal ganglia DNA
and 10-fold dilutions of purified HSV-1 chromosome DNA.
HSV-1 DNA was used to generate a standard curve to determine the number of genome copies per trigeminal ganglion
models the episomal, latent genome. To control for total DNA
content of each sample, the single-copy mouse adipsin gene
was amplified in each sample along with dilutions of mouse
genomic DNA to generate a standard curve. The values for tk
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copy number were normalized to the lowest value of mouse
adipsin copy number to yield the normalized genome copy
per ganglion, which were expressed on a log scale.

2.10. In Vitro Killing of L1210 Cells Transfected with Human
Fas by Mouse Corneas. The use of whole corneas in vitro
to induce Fas-mediated killing has been described [10, 14].
Mouse corneas were placed in 24-well plates with either the
endothelium or epithelium facing up. These corneas were
infected with the KOS strain of HSV-1 or not. To them were
added L1210 cells, which express Fas (2 × 105 /mL were labeled
with 5 𝜇Ci/mL 3 H-thymidine at 37∘ C in complete DMEM for
2 hours). After washing twice they were incubated (2 × 104
cells/determination) with corneas overnight in a 96-well plate
overnight at 37∘ C. The L1210-Fas target cells were harvested
onto microfiber filters and radioactivity counted using a
microplate scintillation counter (TopCount, PerkinElmer
Life Sciences, Boston, MA). Because fragmented DNA associated with apoptosis does not bind to the filters, the counts
associated with the filters reflect nonapoptotic cell DNA only.
The percentage of cells undergoing apoptosis is therefore
defined as
% DNA Fragmentation
= CPM L1210-Fas incubated alone

(1)

CPM L1210-Fas incubated with cornea
× 100.
−
CPM L1210-Fas incubated alone
To confirm that cell killing is due to Fas-FasL interactions,
we added the competitive inhibitor Fas-Fc or an inhibitor
of TNF-mediated killing, TNFR1-Fc, at 10 𝜇g/mL (both from
R&D Systems, Minneapolis, MN) as previously described
[10, 14].
2.11. Statistical Analysis. All statistical analyses were performed with the aid of Sigma Stat for Windows, version 2.0
(Jandel, Corte Madera, CA). The Rank Sum test was used to
compare corneal disease scores. Student’s unpaired 𝑡-test was
used to compare virus titer and antibody titer data. Fisher’s
exact 𝑋2 tests were used to compare limiting dilution assay
data.

∗

40
Cell death (%)

2.9. Flow Cytometric Analysis. Cells were isolated from
corneas as previously described [18]. Briefly, corneas were
excised at 18 and 23 dpi and incubated in PBS-EDTA at
37∘ C for 15 minutes at 37∘ C. Stromas were separated from
overlying epithelium and digested in 84 U collagenase type 1
(Sigma-Aldrich, St. Louis, MO) per cornea for 2 hours at 37∘ C
and then were triturated to form a single-cell suspension.
Suspensions were filtered through a 40-𝜇m cell strainer cap
(BD Labware, Bedford, MA) and washed and then stained.
Suspensions were stained with PerCP-conjugated anti-CD45
(30-F11) and Alexa Fluor700-Gr-1 (RB6-8C5) (from BioLegend, San Diego, CA); FITC conjugated anti-CD4 (RM4-5),
PE-conjugated anti-CD8𝛼 (53–6.7), PE-Cy7-conjugated antiCD11c (HL3) (all BD PharMingen); eFluor450-conjugated
CD11b (M1/70) (from eBiosciences, San Diego, CA). Cells
were then analyzed on a flow cytometer (FACSAria with
FACSDIVA data analysis software; BD Biosciences).

∗

30
20
∗∗

10
0

No cornea Uninfected

HSV

HSV +
Fas-Fc

HSV +
TNFR1-Fc

Figure 1: Infection with HSV-1 induces functional Fas ligand.
Corneas were infected with HSV-1, KOS strain, for 24 hours at which
point [3 H]Thymidine labeled L1210-Fas cells (2 × 104 ) were cultured
in contact with the corneal epithelium in vitro for 20 h at 37∘ C. In
some cultures the chimeric protein Fas-Fc (10 𝜇g/mL) or TNFR1Fc (10 𝜇g/mL) was included for the entire incubation period. The
amount of apoptotic cell death was determined by calculating percent of DNA fragmentation. Each value represents the mean of three
replicate cultures ± SEM, and each culture condition was performed
at least three times. ∗ Infected corneas displayed significantly greater
cell death than did uninfected corneas (𝑃 < 0.02). ∗∗ Addition of FasFc significantly reduced cell death when compared to either HSV
alone (𝑃 < 0.01) or HSV + TNFR1-Fc (𝑃 < 0.02).

3. Results
3.1. Infection of Murine Corneas Results in Increased Fas
Ligand Expression. The first thing that we wished to determine was whether infection with HSV-1 had any effect
on the expression of FasL on the cornea. Recent reports
have demonstrated that FasL can be induced when cells are
exposed to cytokines and stress [28, 29]. In order to do this
we performed a functional assay to determine the ability
of mouse corneas to kill Fas-expressing target cells. Thus
we infected isolated mouse corneas with HSV-1 and then
compared the ability of infected corneas to kill Fas targets
versus uninfected corneas. As demonstrated in Figure 1,
infected corneas were able to kill significantly more Fasexpressing target cells than uninfected corneas. We further
demonstrated that this killing was due to increased FasL
expression as Fas-Fc, which specifically interacts with FasL
blocked killing while TNF-Fc did not (Figure 1). Since these
isolated corneas do not contain significant numbers of CD45+
cells at the time of infection, increased FasL expression will
primarily be on the resident epithelial cells. Thus it is clear
that one way that the cornea attempts to limit inflammation
following HSV-1 infection is by increasing FasL expression
which will more efficiently control the entrance of Fasexpressing inflammatory cells.
3.2. Mice with Mutations in Fas or FasL Have Worse Corneal
Disease. We next compared recurrent HSK between BALBlpr, BALB-gld, and parental BALB/c mice. The mice were
infected with the McKrae strain of HSV-1 and latency was
established. The mice were reactivated 8 weeks following
primary infection. As can be observed in Figure 2, both
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Figure 2: Defective expression of both FasL and to a lesser extent Fas results in increased recurrent HSK following UV-reactivation of a
latent infection with HSV-1, McKrae strain. Eyes of BALB/c wild-type (𝑛 = 20), BALB-lpr (𝑛 = 20), and BALB-gld (𝑛 = 20) mice were
infected with 106 pfu of HSV-1, McKrae strain. Six weeks following infection mice were irradiated with UV-B to reactivate the latent infection.
Corneal opacity (a) and corneal neovascularization (b) were measured and compared between these strains of mice. ∗ Significant virusinduced corneal opacity was observed for BALB-gld at days 14–28 time points when compared to BALB/c controls (𝑃 < 0.01–0.001). BALB-lpr
mice displayed significantly more opacity than did BALB/c controls at days 21–35 (𝑃 < 0.05–0.01). BALB-gld displayed significantly greater
neovascularization at days 14–35 (𝑃 < 0.05–0.001) and BALB-lpr mice had greater neovascularization at days 14, 21, and 35 (𝑃 < 0.05–0.01)
than did BALB/c controls.

3.3. BALB/c Mice with Mutations in Fas and FasL Have
Increased Mortality. In another significant departure from
our previous report, mortality was much greater in those mice
carrying either the lpr or the gld mutation (Figure 4). It should
be noted that the previous report compared C57BL/6 with
mutations in Fas and FasL with their parental B6, but it was
the same strain of HSV-1, namely, McKrae. The reason for
this discrepancy is not known at this time; we suspect that
BALB/c mice, which are more susceptible to both corneal
disease and developing a lethal infection, are more prone
to lethal infection in the absence of Fas-FasL interactions
because there is greater influx of inflammatory cells into the
brain (data not shown).
3.4. The Magnitude of the Inflammatory Infiltrate in Mice with
Mutations in Fas and FasL Is Greater Than Wild-Type Mice
but the Composition of the Infiltrate Is the Same. We also
compared the influx of inflammatory cells into the cornea of
these strains of mice and as expected there were consistently
more CD45+ cells infiltrating the corneas of lpr and gld mice
than in wild-type mice following UV-induced reactivation
(Figure 5(a)). We believe that is due to better control of
the inflammatory infiltrate in wild-type mice that have an

2.00

Corneal opacity

BALB-lpr and BALB-gld mice experienced significantly
worse disease than did wild-type BALB/c mice. This was
consistent with results of primary disease [18], though mice
carrying the gld mutation tended to display consistently
greater disease scores than did mice with the lpr mutation.
A similar pattern of disease was seen in B6 mice that express
mutations in Fas and FasL (Figure 3).
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Figure 3: Similar patterns of disease were seen in C57BL/6 (B6)
mice carrying the gld and lpr mutations following UV-B reactivation. Eyes of B6 wild-type (𝑛 = 20), B6-lpr (𝑛 = 15), and B6gld (𝑛 = 15) mice were infected with 106 pfu of HSV-1, McKrae
strain. Six weeks following infection mice were irradiated with UVB to reactivate the latent infection. Corneal opacity was measured
and compared between these strains of mice. ∗ Significant virusinduced corneal opacity was observed for B6-gld (𝑃 < 0.01–0.001)
at days 14–42 when compared to B6 controls. B6-lpr mice displayed
significantly more opacity than did B6 controls at days 21 and 28
(𝑃 < 0.05–0.01).

intact Fas-FasL interaction. However, since there are no differences in the phenotype of the inflammatory infiltrate
(Figure 5(b)), there does not appear to be a differential
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Table 1: HSV-1 shedding following UV-B reactivation.

EYES
% of positive swabs@
Total shedding days#
Days of shedding/mouse†
Reactivation rate‡
Final day of shedding‖
Trigeminal ganglia
Genome copies × 102 (𝑛)∗∗
Titer day 3 after react. (𝑛)††

Normal BALB/c

BALB-gld

BALB-lpr

11%
7
1.2 ± 0.3
33% (6/18 total)
Day 5

17%
22
2.8 ± 0.25
57% (8/14 total)
Day 10

23%
41
2.9 + 0.6
54% (14/26 total)
Day 10

6.5 ± 0.3 (10)
845 ± 217 (4)

10.4 ± 0.4 (5)
1186 ± 159 (4)

11.1 + 0.3 (5)
1075 + 245 (4)

@

The percent of positive swabs is the percentage of virus-positive eye swabs (140 to 286 eye swabs per group) over the 10-day period following UV-B irradiation.
(𝑃 < 0.01 for both gld and lpr mice.)
#
Total shedding days: number of days of positive swab. (𝑃 < 0.01 for both gld and lpr mice.)
†
Days of shedding/mouse are the number of days that a positive mouse shed virus. (𝑃 < 0.005 for both gld and lpr mice.)
‡
Percentage of reactivation rate is the percentage of mice that were reactivated. (𝑃 < 0.02 for both gld and lpr mice.)
‖
Final day of shedding was the last day that a mouse was positive for a particular group.
∗∗
Mean number of genome copies from real-time PCR analysis. Statistical analysis did not indicate significant differences (𝑃 > 0.05).
††
Titer of virus at day 3 after reactivation.

100

Survival (%)

80
60
40
20
0

0

7

14

BALB/c
BALB-gld

21
28
35
Days after infection

42

49

56

BALB-lpr

Figure 4: Mice expressing mutations in Fas and FasL display
significantly greater mortality than wild-type BALB/c mice. A latent
infection of BALB/c wild-type (𝑛 = 20 mice), BALB-lpr (𝑛 =
20 mice), and BALB-gld (𝑛 = 20 mice) mice was established as
described and mice were observed for mortality for 10 weeks. Data
displayed were compiled from two independent studies. Mortality
for both BALB-lpr and BALB-gld was significantly greater than that
for BALB/c wild-type mice (𝑃 < 0.002).

sensitivity to Fas-FasL-mediated killing among the different
types of cells that make up that infiltrate. Furthermore, those
mice that display significant recurrent disease demonstrate
a predominance of neutrophils regardless of the strain of
mouse (Figure 5(b)). Thus, it would appear that once significant inflammation begins, the make-up of the infiltrate will
be relatively the same regardless of any mutations to Fas or
FasL. It should also be pointed out that serum HSV-1 specific
antibody titers were indistinguishable between these groups
of mice (data not shown).

3.5. Mice with Mutations in Fas and FasL Have Increased
Reactivation and Virus at the Cornea but Do Not Show Differences in Infection of the Trigeminal Ganglia. Interestingly,
when these mice were compared for their ability to shed virus
following UV-induced reactivation, wild-type BALB/c mice
displayed reduced rates of shedding, total number of days
of shedding, duration of shedding, and number of days of
shedding/mouse for positive mice when compared to BALBlpr and BALB-gld mice (Table 1). Furthermore, mice carrying
the lpr and gld mutation consistently shed virus longer
than did wild-type BALB/c mice (Figure 6). In contrast, the
number of viral genomes in trigeminal ganglia was very
similar for all strains (Table 1). Likewise the viral titers at
day 3 after reactivation did not display significant differences
between wild-type BALB/c mice and those carrying either the
lpr or gld mutation (Table 1).

4. Discussion
Herpetic stromal keratitis in the human is primarily a disease
that results from reactivation of HSV-1 from latently infected
trigeminal ganglia neurons [1, 19, 30]. This disease is also
characterized by an immunopathologic attack on the cornea
following such reactivations [19, 30]. The good news is that
most individuals harboring a latent infection of the trigeminal ganglia probably never exhibit overt clinical disease. Thus
it is clear that should virus be reactivated in these clinically
silent individuals their immune response does not result in
a damaging inflammatory response to the cornea. This is
likely the result of several factors, some of which are driven
by the immune response towards HSV-1 that develops in
the infected individual and some due to intrinsic factors
within the cornea that strive to limit strong inflammatory
responses. One of the prime mechanisms the eye uses
to protect itself from T cell-mediated immunopathologic
response is the presence of FasL which induces apoptosis in
Fas+ lymphoid cells [8, 9, 11, 12]. Consequently, those factors
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Figure 5: Inflammatory infiltrate in the corneas of BALB-gld and BALB-lpr mice displays significant increased CD45+ cells, though there are
no qualitative differences in subpopulations of CD45+ cells. Mice were infected in one eye with HSV-1 and reactivated 8 weeks later by UV-B
irradiation. The HSV-infected corneas were removed at days 17 and 23 after irradiation from mice with severe HSK disease and disaggregated
into single-cell suspensions and stained with anti-CD45 (a). The CD45+ cells were gated and further analyzed for staining with anti-CD4,
CD8𝛼, Gr-1, CD11b, CD11c, and F4/80 mAb (b). Cells were analyzed by flow cytometry. Data represents 4 to 6 corneas per group. Significant
differences were seen in CD45+ cells (a) (𝑃 < 0.05–0.02), but not for the percentages of CD45+ subsets (b) (𝑃 > 0.05).
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Figure 6: Daily percent of mice that were shedding virus following
UV-B reactivation. Mice were reactivated by UV-B irradiation and
swabbed daily and the presence of virus for each sample tested.
Mice containing mutations in Fas (lpr) and FasL (gld) shed virus
significantly longer than wild-type BALB/c mice (𝑃 < 0.01).

that either directly or indirectly lead to changes in FasL
expression would greatly affect the cornea’s ability to restrict
inflammatory infiltrates. It is known that some factors,

such as inhibitors of matrix metalloproteases, stabilize FasL
expression which results in increased surface expression of
FasL and a concomitant increase in the ability of the cornea
or the choroid to control inflammatory [31] and angiogenic
invasion [32]. Likewise the production of IL-18 has also
been recently shown to induce FasL expression [29]. We
report here that ex vivo infection of corneas with HSV-1 also
increases the functional expression of FasL. Thus one might
speculate that one way that the cornea attempts to control damaging inflammatory invasion is by increasing FasL
expression following exposure to infectious agents.
We and others have reported that lack of functional FasFasL-mediated apoptotic ability in the eye most often leads
to increased inflammatory responses [8, 9, 12], increased
corneal allograft rejection [12, 33], increased acute HSK [18],
increased neovascularization [10, 13, 14], and the inability to
develop systemic tolerance following injection of antigen into
the anterior chamber [8]. Thus it is not surprising that mice
that are defective in Fas-FasL display increased recurrent
HSK.
This observation is partially consistent with what was
observed in these mice during acute HSK [18]. Namely, they
experience significantly increased disease when compared to
wild-type mice. In spite of the general similarity in results
there were some potentially important differences. First,
recurrent disease was more pronounced in gld mice than that
observed in lpr mice. This difference, while not statistically
significant, was consistent for mice on both the BALB/c and
the B6 backgrounds. The reason for this difference has not
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been determined and will be the subject of future studies.
None the less it might relate to the fact that gld mice do not
control neovascularization as well as lpr mice do [14]. It was
determined that this was a consequence of the leakiness of the
lpr mutation in terms of vascular endothelium’s expression
of Fas [14]. Consequently, while both lpr and gld mice
would demonstrate a similar lack of control of inflammatory
cell infiltrate, gld mice would have more neovascularization
which could result in overall greater disease. In addition,
since infection with HSV-1 increases the expression of FasL
on the cornea, one might expect the gld phenotype to have
a more pronounced effect on controlling any population of
Fas-expressing cells to enter the infected cornea.
In addition to the minor differences in corneal disease
between lpr and gld mice was the remarkable difference
in mortality seen between BALB/c and both BALB-lpr and
BALB-gld mice when they were infected with the neurovirulent McKrae strain of HSV-1. What is even more surprising
was that this difference in mortality occurs despite the fact
that all strains of mice were provided with neutralizing
antibody. We had previously reported that lpr and gld mice
on the B6 background that were acutely infected with the
McKrae strain of HSV-1 were more resistant than wild-type
B6 mice [18]. This intriguing strain-associated difference
could be a clue to how different genetic backgrounds can
greatly alter the ability of the HSV-1 for traffic within the
infected host. We had believed that the relative resistance
seen in B6-lpr and B6-gld mice was due to the lack of
apoptotic cell death that might be inducing tolerance towards
HSV-1 as has been reported for other types of infections
[34, 35]. This does not appear to be the case with Fas/FasL
mutations on the BALB/c background. Therefore, it is entirely
possible that the increased inflammation seen in the cornea
may also occur wherever the virus spreads and thus play
a role in compromising the blood-brain barrier allowing
increased viral penetration of the brain followed by entrance
of inflammatory cells leading to death by encephalitis. At
present we do not have direct data indicating that this is
the case, but we are currently planning studies to better
understand the increased mortality associated with BALB/c
mice expressing mutations in Fas or FasL.
In addition to these anti-inflammatory responses that
are specific to the eye, it is also well established that host
T cells eliminate viral infected cells either by the perforingranzyme pathway [36] or via apoptosis mediated by the
interaction of FasL on effector cells with Fas expressed by
virally infected cells [37, 38]. Thus it is also possible that mice
defective in killing via Fas-FasL would display reduced ability
to kill virally infected targets. This could be one of the reasons
why virus persists in the corneas of both gld and lpr mice.
It might also provide another explanation for why gld and
lpr mice have increased mortality when infected with the
McKrae strain of HSV-1. That said, lack of a functional FasFasL interaction does not prevent these mice from clearing
infectious virus from the cornea as evidenced by the fact that
infectious virus is not detectible in the corneas of reactivated
mice after 10 days following reactivation.
It should also be pointed out that characterization of
the inflammatory infiltrate in mice suffering from significant
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corneal disease illustrates two concepts. The first is that, overall, the corneas of wild-type BALB/c mice have quantitatively
fewer CD45+ cells than do those mice with mutations in
Fas or FasL. Secondly, when mice with significant disease
are analyzed qualitatively there are no significant qualitative
differences between wild-type and mutant mice (Figure 5).
All mice with significant disease, regardless of their genotype,
have infiltrates that consist of large numbers of neutrophils
and much lower numbers of T cells, macrophages, and dendritic cells. Thus, once again, it appears that corneal disease
is best associated with the presence of large numbers of
neutrophils that infiltrate the cornea [4, 18].
Previous work from this and other investigators have
shown that development of an antibody response against
HSV-1 can protect mice from the development of severe HSK
[20, 39, 40]. As a consequence we tested antibody responses
in BALB/c, BALB-lpr, and BALB-gld mice to determine if lpr
or gld mice had impaired anti-HSV-1 responses. However,
no differences were observed between these strains (data not
shown), indicating that the ability to develop an anti-HSV-1
antibody response was not involved.
Taken together, these studies document that mice
with impaired Fas-FasL interactions develop significantly
increased HSK following UV-B induced reactivation. This
response is slightly more pronounced in mice with mutations
in FasL than in Fas. The mechanism responsible for increased
disease is likely due to increased inflammation of the cornea
not by the qualitative nature of that inflammation. This
Increased inflammation is likely driven by two factors: one
is the reduced control of infiltrating inflammatory cells and
second a prolonged presence of infectious virus in the cornea.
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